All In Biotech

Drug Trial Radar · NCT07029945

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Biojiva LLCIndustry
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration. The study is conducted in phases 1 and 2, focusing on assessing both safety (tolerability) and effectiveness (efficacy) of the treatment. Participants: Adults with geographic atrophy due to age-related macular degeneration. Treatment: BRX011 or Placebo is taken once daily as per the protocol. Duration: The study involves multiple visits over 96 weeks to monitor participants' health and response to treatment. Safety Monitoring: Regular checks for adverse events and health status to ensure participant well-being. Checks will include examination of vital signs, clinical labs, ocular exams, and ocular imaging. Primary Outcome Measure: Efficacy of BRX011 in the annual rate of change in the square root of GA area, as specified in the protocol.

Conditions

  • Geographic Atrophy

Interventions

  • BRX011Drug

    Subjects will ingest BRX011 orally, as capsules.

  • PlaceboDrug

    Subjects will ingest Placebo orally, as capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual rate of change in the square root of GA areaTime frame: Baseline (Day 0) to Week 96

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants - PHX

    Gilbert, Arizona · Recruiting

  • Associated Retina Consultants

    Phoenix, Arizona · Recruiting

  • Retina Specialists of Mississippi - Hattiesburg

    Hattiesburg, Mississippi · Not yet recruiting

  • Sierra Eye Associates

    Reno, Nevada · Not yet recruiting

  • Retina Associates of Cleveland - Beachwood

    Beachwood, Ohio · Recruiting

  • Retina Associates of Cleveland

    Cleveland, Ohio · Not yet recruiting

  • Retina Associates of Cleveland - Middleburg Heights

    Middleburg Heights, Ohio · Not yet recruiting

  • Retina Research Institute of Texas

    Abilene, Texas · Recruiting

  • Valley Retina Institute, PA

    McAllen, Texas · Recruiting

  • Retina Research Center of Southern Utah

    St. George, Utah · Not yet recruiting

  • Spokane Eye Clinic

    Spokane, Washington · Not yet recruiting

  • Eye Clinic Albury Wodonga

    Albury, New South Wales, Australia · Not yet recruiting

  • Nexus Eye Care

    Baulkham Hills, New South Wales, Australia · Not yet recruiting

  • Retina & Macula Specialists

    Hurstville, New South Wales, Australia · Not yet recruiting

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia · Not yet recruiting

  • Centre for Eye Research Australia (CERA)

    East Melbourne, Victoria, Australia · Not yet recruiting

  • Retina Specialists Victoria

    Rowville, Victoria, Australia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.